Slide 1: FY22 Half-Yearly Financial Results Presentation
FY22 Half-Yearly Financial Results Presentation Half Year Results - 31 March 2022 Strong base, opportunities emerging Hancock & Gore Ltd (ASX: HNG)
Slide 2: Important Notices
IMPORTANT NOTICES Not investment advice The information contained in this presentation is not investment or financial product advice (nor tax, accounting or legal advice) nor is it a recommendation to acquire securities in HNG. This presentation does not and will not form any part of any contract fo
Slide 3: Performance Highlights for the Half-Year Ended 31 March 2022
PERFORMANCE HIGHLIGHTS FOR THE HALF-YEAR ENDED 31st MARCH 2022 12% TOTAL SHAREHOLDER RETURN $2.5m NET PROFIT AFTER TAX 13% NTA PER SHARE GROWTH $62.1m NTA VALUE 45% FUM GROWTH $0.28 NTA PER SHARE 34% OF NTA IN CASH & LISTED SECURITIES
Slide 4: H1FY22 Highlights
H1FY22 HIGHLIGHTS • H1 FY 22 ~$2.5 M NPAT driven by ASX Tactical Opportunities portfolio, and revaluation of unlisted investments to reflect underlying performance • Strengthened balance sheet via $15 million equity raise in late CY21/early CY22 • Strong EBIT performance of Pegasus and Mountcastle.
Slide 5: Investment Team
INVESTMENT TEAM 100+ years of collective investment experience SANDY BEARD NICHOLAS ATKINSON PHILLIP CHRISTOPHER JOSEPH CONSTABLE MICHAEL BOWER EXECUTIVE CHAIRMAN INVESTMENT DIRECTOR INVESTMENT DIRECTOR PORTFOLIO MANAGER COMPANY SECRETARY • 30+ years of investment • 25+ years of experience • 12+ yea
Slide 6: H&G Investment Management Highlights
H&G INVESTMENT MANAGEMENT HIGHLIGHTS 45% Increase in FUM driven by a new mandate win and High Conviction Fund positive performance Launching a strategic transformation of the HCF that will add assets/FUM & launch a LIC vehicle Launched inaugural syndication deal expected to close before June 22. Dea
Slide 7: Established Value Creation Cycle
ESTABLISHED VALUE CREATION CYCLE Targeting 15% p.a. minimum compound returns Experienced Management /Investment Reinvest expanded team capital plus new capital Recurrent capital growth Proprietary deal flow & from PE & Syndication investment opportunities outperformance Build layers of yield from co
Slide 8: Portfolio Activity Sets Platform for Growth in FY23 and Beyond
PORTFOLIO ACTIVITY SETS PLATFORM FOR GROWTH IN FY23 AND BEYOND Focus in H1 on driving key portfolio activity and identifying new investments Anagenics Ltd (ASX: Name Mountcastle/LW Reid Pegasus Healthcare NewPackagingCo Mint Payments T-shirt Ventures AN1) Type Defensive Yield Defensive Growth Growth
Slide 9: Investments Overview
INVESTMENTS OVERVIEW PROFORMA BUSINESS INDUSTRY VALUATION PORTFOLIO % Mountcastle School wear $16.7m 27% Pegasus Healthcare Health $9.6m 15% Anagenics Ltd (ASX:AN1) Wellness & Beauty $1.7m 3% Mint Payments Payments Technology $3.1m 5% SPOS Retail POS $2.2m 4% T-Shirt Ventures Health $2.0m 3% ASX Lis
Slide 10: FY22 and Beyond
FY’22 AND BEYOND H&G has strengthened our executive team and built a solid and deep foundation for long term growth 1 PRIVATE INVESTMENTS 2 LISTED INVESTMENTS 3 FUNDS MANAGEMENT 4 OTHER • Continue targeting at least • Continue >20% p.a. • Continue FUM growth with • Increase advisory / ECM 15% p.a. r
Slide 11: H1FY22 Income Statement
H1FY22 INCOME STATEMENT Six months to 31st March 2022 Realised & Unrealised Gains on Investments $3.3m Funds Management & other fee revenue $0.3m Other Income $0.5m Dividends $0.2m Expenses ($1.7m) Net Profit Before Tax $2.6m Net Profit After Tax $2.5m
Slide 12: H1FY22 Balance Sheet
H1FY22 BALANCE SHEET As at 31st March 2022 Cash $12.0m Listed Investments $9.3m Unlisted Investments $34.9m $62.1M Loan Note $5.2m Intangibles $0.7m Other Assets & Liabilities Net $0.8m NET TANGIBLE Net Assets $62.9m ASSETS
Slide 13: Mr. Sandy Beard, Executive Chairman
MR. SANDY BEARD EXECUTIVE CHAIRMAN 0412 308 263 www.hancockandgore.com.au